Israel-based

Teva Pharmaceutical

(TEVA) - Get Report

said on Monday that it had received tentative U.S. Food and Drug Administration approval for a generic treatment designed to prevent heart attacks and strokes.

The drug company's Pravastatin tablets are a generic version of

Bristol-Myers Squibb's

(BMY) - Get Report

Pravachol, which had U.S. sales of about $1.3 billion in 2001.

The company plans to offer the treatment in 10-milligram, 20-mg, and 40-mg tablets.

Shares of Teva were up about 1.2% to $63.35 on the news in premarket trading after closing at $62.60 Friday.